From the Writing
Newspaper La Jornada
Monday, April 25, 2022, p. eleven
AstraZeneca’s drug AZD7442, a combination of long-acting antibodies, reduced the risk of developing symptomatic COVID-19 by 77 percent, and no cases of severe illness or related deaths were detected during six-month follow-up. This is the result of the trial called Provent, carried out at 87 points in the United States, United Kingdom, Spain, France and Belgium.
The AstraZeneca laboratory reported in a statement that AZD7442 concentrations remained elevated in serum six months after administration, supporting that a single dose could provide protection against the coronavirus for at least six months.
The information was disclosed in New England Journal of Medicinein which lead researcher Myron J. Levin, professor of pediatrics and medicine at the University of Colorado School of Medicine, United States, stated that while anti-Covid vaccines have been highly effective in reducing hospitalization and death, Cases continue to rise and many people remain at high risk, including those who are immunosuppressed and those who cannot be vaccinated.
For those who cannot be vaccinated
An easily administered intramuscular dose of AZD7442 could provide long-lasting protection to vulnerable populations. Furthermore, AZD7442 has been shown to neutralize the dominant variant of covid BA.2.
The report indicated that about 2 percent of the world’s population are estimated to be at increased risk of an inadequate response to coronavirus vaccination, and may particularly benefit from pre-exposure prophylaxis with AZD7442.
